Physician profile
Jenny O Sobera
NPI 1063460343
$94,335.13
in general payments reported to CMS, 2019-2025
45 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $7,114 · 2021: $9,154 · 2022: $24K · 2023: $7,662 · 2024: $9,514 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $5,826 · Travel and Lodging: $1,832 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,852.50 |
| Food and Beverage | $5,826.03 |
| Travel and Lodging | $1,831.65 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $49,858.11 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $19,623.34 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $8,733.34 | 2019-2025 | Duobrii, Arazlo, Siliq |
| Allergan, INC. | $4,501.79 | 2019-2022 | |
| Abbvie INC. | $2,558.47 | 2019-2025 | Botox, Rinvoq |
| Merz North America, INC. | $932.70 | 2019-2025 | |
| Galderma Laboratories, L.P. | $903.51 | 2019-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $734.07 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $671.50 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $566.74 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $494.56 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $437.51 | 2019-2025 | |
| Genzyme Corporation | $417.62 | 2019-2022 | |
| Lilly USA, LLC | $415.46 | 2019-2025 | Taltz, Ebglyss |
| Vyne Pharmaceuticals INC. | $347.98 | 2020-2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $346.55 | 2022-2024 | Vtama |
| Journey Medical Corporation | $307.73 | 2021-2023 | |
| Amgen INC. | $280.62 | 2021-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $266.03 | 2024-2025 | Daxxify |
| Ucb, INC. | $221.48 | 2019-2025 | Bimzelx, Cimzia |
| Lumenis Be INC | $220.56 | 2023 | M22 |
| Biofrontera INC. | $195.56 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $168.87 | 2019-2020 | |
| Janssen Biotech, INC. | $138.75 | 2023 | Tremfya |
| Organon LLC | $129.68 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $117.51 | 2022-2024 | Sotyktu |
| Epi Health, LLC | $90.46 | 2020-2022 | |
| Strata Skin Sciences, INC. | $86.52 | 2019-2023 | Xtrac |
| Verrica Pharmaceuticals INC. | $73.44 | 2024 | Ycanth |
| Almirall LLC | $70.33 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $67.70 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $58.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $56.55 | 2023-2024 | Dupixent, Libtayo |
| Celgene Corporation | $32.38 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $29.87 | 2019 | |
| Nabriva Therapeutics, Plc | $27.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $23.21 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $23.12 | 2019 | |
| Organogenesis INC. | $20.13 | 2021 | |
| Dusa Pharmaceuticals, INC. | $18.39 | 2019 | |
| Sandoz INC. | $18.16 | 2020 | |
| Botanix Sb INC | $17.98 | 2025 | Sofdra |
| Stemline Therapeutics INC. | $15.76 | 2020 | |
| Mission Pharmacal Company | $14.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Sobera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.